

ADVANCES IN CANCER SIGNAL TRANSDUCTION AND THERAPY

Editors:

Manoj K. Pandey

Vijay P. Kale

Bentham Books

Recent Advances in Signal Transduction Research and Therapy

(Volume 1)

Edited by

Manoj K. Pandey

*Department of Biomedical Sciences
Cooper Medical School of Rowan University
Camden, NJ 08103
USA*

&

Vijay P. Kale

*Translational Safety And Bioanalytical Sciences
Amgen Inc.
South San Francisco, CA 94080
USA*

Recent Advances in Signal Transduction Research and Therapy

Volume # 1

Advances in Cancer Signal Transduction and Therapy

Editors: Manoj K. Pandey & Vijay P. Kale

ISSN (Online): 2737-4432

ISSN (Print): 2737-4424

ISBN (Online): 978-981-14-5811-8

ISBN (Print): 978-981-14-5809-5

ISBN (Paperback): 978-981-14-5810-1

© 2020, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iii
CHAPTER 1 WNT SIGNALING IN BREAST CANCER ONCOGENESIS, DEVELOPMENT AND PROGRESSION	1
<i>Norman Fultang and Bela Peethambaran</i>	
INTRODUCTION	1
Overview	1
Wnt Biosynthesis and Regulation	2
TYPES OF PATHWAYS	3
The Canonical Wnt Signaling Pathway in Breast Cancer	3
Non-canonical Wnt Pathways in Breast Cancer	4
Regulators of Wnt Signaling	5
Wnt and Breast Cancer Stem Cells	5
ROLE OF WNT SIGNALING IN BREAST CANCER TUMORIGENESIS AND PROGRESSION	6
ANIMAL MODELS AND CLINICAL SIGNIFICANCE OF WNT SIGNALING IN BREAST CANCER	7
WNT SIGNALING IN TRIPLE-NEGATIVE BREAST CANCER	8
NATURAL COMPOUNDS TARGETING WNT PATHWAYS AS CANCER THERAPEUTICS	9
SMALL MOLECULES AND NOVEL THERAPEUTICS THAT TARGET WNT SIGNALING	12
CONCLUSION AND FUTURE DIRECTIONS	13
ABBREVIATIONS	14
CONSENT FOR PUBLICATION	16
CONFLICT OF INTEREST	16
ACKNOWLEDGEMENTS	16
REFERENCES	16
CHAPTER 2 CXCR4 SIGNALING AND ITS IMPACT ON TUMOR PROGRESSION AND METASTASIS IN BREAST CANCER	29
<i>Dayanidhi Raman, Cory M. Howard, Sangita Sridharan and Augustus M.C. Tilley</i>	
INTRODUCTION	29
CXCL12-CXCR4 AXIS	30
CXCR4 PATHWAYS OPERATING IN BREAST CANCER	33
PI3K Pathway	33
<i>AKT (or Protein Kinase B) Signaling Node</i>	33
<i>mTOR Node</i>	34
MAPK Pathway	35
<i>Oncoprotein Translation by MAPKs</i>	35
<i>Epithelial-mesenchymal Transition (EMT) and Cell Migration</i>	36
<i>Inactivation of ERK1/2</i>	36
C-SRC Pathway	37
JAK-STAT Pathway	37
Cross-talk of CXCR4 with Other Receptor and Non-receptor Tyrosine Kinases and its Interaction with Specific Adaptors	38
Stromal Cell Recruitment to the TME	38
Therapeutic Implications	39
CONCLUSION	41

CONSENT FOR PUBLICATION	41
CONFLICT OF INTEREST	41
ACKNOWLEDGEMENTS	41
REFERENCES	41
CHAPTER 3 EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING IN COLON	
CANCER	51
<i>Avtar S. Meena and Pradeep K. Shukla</i>	
COLORECTAL CANCER AND RISK FACTORS	51
EGFR SIGNALING IN CRC	52
EGF-like Growth Factors	55
MAPK Signaling	56
PI3K/ Akt Signaling	56
Emerging Role of EGFR in the Development of Colon Cancer	57
EGFR THERAPIES	59
Anti-EGFR Receptor Therapy	59
Anti-EGFR Monoclonal Antibodies	62
<i>Cetuximab</i>	62
<i>Panitumumab</i>	63
Anti-EGFR Tyrosine Kinase Inhibitors	64
<i>Erlotinib</i>	64
<i>Gefitinib</i>	64
MECHANISM OF RESISTANCE TO ANTI-EGFR THERAPY	65
Low Expression of Amphiregulin, Epiregulin, and EGFR Gene Copy Number	66
EGFR Downstream Effectors	67
<i>RAS</i>	67
<i>RAF</i>	67
<i>PIK3CA</i>	68
<i>PTEN</i>	68
ROLE OF EGFR IN OTHER DISEASE MODELS	69
EGFR and Probiotics	69
EGFR and Inflammation	69
EGFR and Glutamine	70
FUTURE DIRECTION	71
CONCLUSION	72
CONSENT FOR PUBLICATION	73
CONFLICT OF INTEREST	73
ACKNOWLEDGEMENTS	73
REFERENCES	73
CHAPTER 4 TARGETING THE PI3K/AKT/MTOR SIGNALING PATHWAY IN	
HEPATOCELLULAR CARCINOMA: CURRENT STATE AND FUTURE TRENDS	85
<i>Neelam Yadav and Yoganchal Mishra</i>	
INTRODUCTION	85
Risk Factors for HCC	86
Pathophysiology	86
Basic Signaling Pathways	87
PI3K/AKT/MTOR SIGNALING PATHWAY	88
Activation of PI3K/Akt/mTOR Pathway	90
Targeting PI3K/Akt/mTOR Signaling Pathway	90
<i>Targeting PI3K</i>	90
<i>Targeting Akt</i>	91

<i>Targeting mTOR</i>	92
Clinical Perspectives of the Current State	92
Challenges in Targeting PI3K/Akt/mTOR Pathway	93
CONCLUSION AND FUTURE PERSPECTIVE	94
CONSENT FOR PUBLICATION	94
CONFLICT OF INTEREST	94
ACKNOWLEDGEMENTS	94
REFERENCES	94
CHAPTER 5 MAPK SIGNALING PATHWAY: A CENTRAL TARGET IN PANCREATIC CANCER THERAPEUTICS	99
<i>Sahdeo Prasad and Sanjay K. Srivastava</i>	
INTRODUCTION	99
Activation of the MAPK Pathway	100
MAPK PATHWAY IN PANCREATIC CANCER PROGRESSION	102
ROLE OF MAPK INHIBITORS IN PANCREATIC CANCER THERAPEUTICS	105
CONCLUSION	108
CONSENT FOR PUBLICATION	108
CONFLICT OF INTEREST	108
ACKNOWLEDGEMENTS	108
REFERENCES	109
CHAPTER 6 ROLE OF NF-κB ACTIVATION IN MULTIPLE MYELOMA AND OTHER HEMATOLOGICAL MALIGNANCIES	114
<i>Loukik Arora, Frank Arfuso, Alan Prem Kumar and Gautam Sethi</i>	
INTRODUCTION	114
STRUCTURE AND SIGNALING CASCADE OF NF-κB PROTEINS	115
NF-κB Activation and Signaling	115
Canonical or Classical Pathway	116
Non-canonical Pathway	117
Inhibition of the NF-κB Pathway	117
ROLE OF NF-κB IN SOLID TUMORS AND HEMATOLOGICAL MALIGNANCIES	117
Role of NF-κB in Multiple Myeloma	118
NF-κB Activation in Leukemia and Lymphoma	119
Potential Pharmacological Targeting of NF-κB Pathway	120
Receptor Blockers and Upstream Signaling Inhibitors	120
IKK Inhibitors	121
Ubiquitination and Proteasome Inhibitors	121
Direct NF-κB and Nuclear Activity Inhibitors	121
Non-steroidal Anti-inflammatory Drugs	122
Glucocorticoids and Immunomodulators	122
Natural Products	122
CONCLUSION	122
LIST OF ABBREVIATIONS	123
CONSENT FOR PUBLICATION	124
CONFLICT OF INTEREST	124
ACKNOWLEDGEMENTS	124
REFERENCES	124

CHAPTER 7 BRUTON'S TYROSINE KINASE SIGNALING AND ADVANCEMENT IN MULTIPLE MYELOMA THERAPY	131
<i>Krishne Gowda, Max Von Suskil, Omar S. Al-Qdat, Jennifer Dang, Kuntal Bhowmick Prachi S. Narayan, Shantu G Amin and Manoj K. Pandey</i>	
INTRODUCTION	132
THE BTK SIGNALING PATHWAY	133
Structure and Activation of BTK	133
Role of BTK in B Cell Receptor Signaling	134
BTK in Other Signaling Pathways	135
<i>Chemokine Receptors</i>	135
<i>Toll-like Receptors</i>	137
Fc Receptor Signaling	137
ROLE OF BTK SIGNALING IN HEMATOLOGICAL MALIGNANCIES	137
Chronic Lymphocytic Leukemia	137
Mantle Cell Lymphoma	139
Waldenström's Macroglobulinemia	139
Diffuse Large B-cell Lymphoma	139
Multiple Myeloma	140
THE DEVELOPMENT OF BTK INHIBITORS	141
Ibrutinib	141
Acalabrutinib (ACP-196]	142
BGB-3111	143
Tirabrutinib (Ono/GS-4059]	144
KS99	144
CONCLUSIONS AND FUTURE DIRECTIONS	145
CONSENT FOR PUBLICATION	145
CONFLICT OF INTEREST	146
ACKNOWLEDGEMENTS	146
ABBREVIATIONS	146
REFERENCES	149
CHAPTER 8 THE TUMOR MICROENVIRONMENT MEDIATED SIGNALING PATHWAYS IN THE PROGRESSION OF ACUTE MYELOID LEUKEMIA	159
<i>Anup S. Pathania, Rachel Weber and Kishore B. Challagundla</i>	
INTRODUCTION	160
THE TUMOR MICROENVIRONMENT AND ACUTE MYELOID LEUKEMIA LEUKEMIC CELLS AND THE MODULATION OF THE TUMOR MICROENVIRONMENT	162
THE TUMOR MICROENVIRONMENT AND ACUTE MYELOID LEUKEMIA THERAPY RESPONSE	163
ACUTE MYELOID LEUKEMIA AND EXOSOMES	164
EXOSOMES WITHIN THE ACUTE MYELOID LEUKEMIA MICROENVIRONMENT	165
THE 'CMYC' AND 'ACUTE MYELOID LEUKEMIA'	169
THE EXOSOMES AND C-MYC IN THE PROGRESSION OF ACUTE MYELOID LEUKEMIA	172
CONCLUSIONS AND OUTLOOK	174
CONSENT FOR PUBLICATION	175
CONFLICT OF INTEREST	175
ACKNOWLEDGEMENTS	175
REFERENCES	175
SUBJECT INDEX	184

PREFACE

Every year, almost 10 million people succumb to death around the world due to one or the other type of cancers. Hundreds of laboratories with thousands of scientists are trying to understand the ever-enigmatic biology of cancer cells, which is the basis for developing new therapies for cancer. Discovery of antifolates aminopterin in 1947 and methotrexate (aka amethopterin) in 1948 as potential anticancer agents by Drs. Yellapragada Subbarow and Sydney Farber not only initiated the era of chemotherapy but the discovery of these synthetic agents also infused the hope that cancers can be treated with synthetic chemicals. In the past more than seven decades, we have witnessed the journey of cancer therapy that started from nonspecific chemotherapy (*e.g.* antifolates) to targeted biologic agents (*e.g.* monoclonal antibodies) and now the era of personalized treatment (*e.g.* CART cells) and immunotherapy. However, deeper understanding of the signal transduction within the cancer cells, and between cancer cells and their surrounding tumor microenvironment has remained central to the development of therapies.

In the present volume 1 titled ‘**Advances in Cancer Signal Transduction and Therapy**’ of the book series ‘Recent advances in signal transduction research and therapy’, we attempted to review recent advances in select cancer signal transduction pathways that have been targeted or could be potential targets for developing therapeutics for cancers. It would be too exhaustive to cover all the signaling pathways in all cancer types and we do not intend to do so, and due to the very rapidly progressing research on cancer signaling and therapy, we have no doubt that new discoveries will have been made by the time this book is published.

In the first chapter of this book, **Fultang *et al.***, dive into the role of Wingless and Int-1 (Wnt) signaling in breast cancer oncogenesis. Moreover, the authors also review the current inhibitors of Wnt signaling that are under investigation. The C-X-C chemokine receptor type 4 (CXCR4) signaling is critical in hematological malignancies, while its role in breast cancer is still unraveling. In the second chapter **Raman *et al.***, explain the intersection of CXCR4 signaling with other signaling pathways such as Phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), cellular Src (c-Src) and Janus kinases-signal transducer and activator of transcription proteins (JAK-STAT) in breast cancer progression and metastasis. A key role of epidermal growth factor receptor (EGFR) signaling in cell proliferation and survival in various cancers is now well known. Here in the third chapter, **Meena *et al.***, discuss the role of EGFR in colon cancer and its prospective importance as a target for colon cancer therapy. The critical role of PI3K/AKT (protein kinase B)/mammalian target of rapamycin (mTOR) signaling pathway in various cancers has attracted cancer researchers for a long time. **Yadav and Mishra** elucidate the PI3K/AKT/mTOR signaling in hepatocellular carcinoma and review the various drugs under investigations that target this pathway in the fourth chapter. The MAPK pathway is one of the key survival pathways that have been targeted to develop cancer therapeutics. In chapter 5, **Prasad and Srivastava** review MAPK signaling in pancreatic cancer and therapeutic agents under investigation. Aberrant regulation and activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) has been implicated in several cancers, inflammatory and autoimmune disorders, and erroneous immune system development. In chapter 6, **Arora *et al.***, summarize the role of NF- κ B activation specifically in multiple myeloma and various strategies developed for its potential pharmacological intervention to abrogate the process of cancer cell proliferation. Recently, small-molecule inhibitors of Bruton’s tyrosine kinase (BTK) such as ibrutinib have shown an impressive anti-tumor activity in clinical studies in patients with various B cell malignancies. BTK is crucial in B lymphocyte development, differentiation and oncogenic signaling. In chapter 7, **Gowda *et al.***, elucidate the role of BTK in B cell malignancies and highlight the

ii

current progress in the discovery of small molecule BTK inhibitors. Finally, in the last chapter of this book, **Pathania *et al.***, discuss the interconnection between exosomes, tumor microenvironment and cMyc transcription factor, and therapeutic strategies to break that nexus.

We sincerely hope that you will enjoy diving into this book.

Manoj K. Pandey

Department of Biomedical Sciences,
Cooper Medical School of Rowan University,
Camden, NJ 08103,
USA

&

Vijay P. Kale

Translational Safety And Bioanalytical Sciences
Amgen Inc.
South San Francisco, CA 94080
USA

LIST OF CONTRIBUTORS

Alan Prem Kumar	Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Anup S. Pathania	Department of Biochemistry and Molecular Biology & The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, USA
Augustus M.C. Tilley	Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, USA
Avtar S. Meena	Department of Pure and Applied Physics, CSIR-Centre for Cellular and Molecular Biology (CCMB) Habsiguda, Hyderabad, India
Bela Peethambaran	Department of Biological Sciences, University of the Sciences, Philadelphia, USA
Cory M. Howard	Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, USA
Dayanidhi Raman	Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, USA
Frank Arfuso	Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Perth, Australia
Gautam Sethi	Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Jennifer Dang	Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, USA
Krishne Gowda	Department of Pharmacology, Penn State College of Medicine, Hershey, USA
Kishore B. Challagundla	The Children's Health Research Institute, University of Nebraska Medical Center, Omaha, USA
Kuntal Bhowmick	Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, USA
Loukik Arora	Department of Pharmacology, Yong Loo Lin School of Medicine. National University of Singapore, Singapore
Manoj K. Pandey	Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, USA
Max Von Suskil	Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, USA
Neelam Yadav	Department of Biochemistry, Rammanohar Lohia Avadh University, Faizabad, India
Norman Fultang	Department of Biological Sciences, University of the Sciences, Philadelphia, USA
Omar S. Al-Odat	Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, USA
Prachi S. Narayan	Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, USA

iv

- Pradeep K. Shukla** Department of Physiology, University of Tennessee Health Science Center, Memphis, USA
- Rachel Weber** Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, USA
- Sahdeo Prasad** Department of Immunotherapeutics and Biotechnology, and Center for Tumor Immunology and Targeted Cancer Therapy, Texas Tech University Health Sciences Center, Abilene, USA
- Sangita Sridharan** Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, USA
- Sanjay K. Srivastava** Department of Immunotherapeutics and Biotechnology, and Center for Tumor Immunology and Targeted Cancer Therapy, Texas Tech University Health Sciences Center, Abilene, USA
- Shantu G Amin** Department of Pharmacology, Penn State College of Medicine, Hershey, USA
- Vijay P. Kale** Translational Safety And Bioanalytical Sciences, Amgen Inc., South San Francisco, CA 94080, USA
- Yoganchal Mishra** Department of Biochemistry, Rammanohar Lohia Avadh University, Faizabad, India

Wnt Signaling in Breast Cancer Oncogenesis, Development and Progression

Norman Fultang and Bela Peethambaran*

Department of Biological Sciences, University of the Sciences, Philadelphia, PA, USA

Abstract: Wnt signaling regulates several cellular processes, including differentiation, proliferation, and stem cell pluripotency. Mutations in Wnt signaling are known to lead to tumor initiation and progression. Wnt/ β -catenin signaling is dysregulated in breast cancer, where it has been shown to mediate oncogenic progression. In this review, the canonical and non-canonical pathways of Wnt/ β -catenin signaling, and their regulation of breast cancer oncogenesis and progression are described. During the last decade, several small molecules and natural compounds have shown to interfere with Wnt signaling and demonstrate potential as Wnt-targeting therapeutic agents. This review also highlights these molecules, some of which are in clinical trials. Finally, strategies of using these molecules in combination therapies with other drug agents are discussed.

Keywords: β -catenin, Breast cancer, Canonical and Non-canonical pathways, Mutations, Oncogenesis, Proliferation, Stem cell pluripotency, Wnt signaling.

INTRODUCTION

Overview

The Wnt/ β -catenin pathway is a crucial and highly conserved pathway governing the processes of growth, development, and cell fate [1]. An ever-increasing body of evidence suggests a vital role for Wnt/ β -catenin signaling in the oncogenesis, development and progression of cancer [2]. This review will summarize recent findings on the role of this pathway in breast cancer and discuss the emerging therapeutic approaches targeting Wnt signaling.

The Wnt signaling cascade is an evolutionarily conserved pathway. It was first discovered to be responsible for spontaneous mammary hyperplasia and tumor formation in mice after pro-viral insertion in the int-1 locus [3]. A few years later,

* **Corresponding author Bela Peethambaran:** Department of Biological Sciences, University of the Sciences, Philadelphia, PA, USA; Tel: 215-596-8923; Fax: 215-596-8710; E-mail: b.peethambaran@uscience.edu

the Wingless gene responsible for segment polarity in *Drosophila melanogaster* was found to be a homolog of int-1. Hence the int/Wingless family was named *Wnt* [4, 5]. Wnt proteins are encoded by 19 different Wnt genes with sequences sharing a high degree of homology [6]. These proteins are known to bind to cellular receptors during embryonic development and mediate several processes, such as cell proliferation, survival, migration, polarity, cell fate, and self-renewal [7]. Wnt can activate distinct signaling pathways, which include a β -catenin dependent or canonical pathway, and a β -catenin independent or non-canonical pathway [4, 7]. Wnt ligands bind primarily to multiple Frizzled (Fzd) receptors [8], but other Wnt co-receptors include members of the low density lipoprotein related protein 5 and 6 (LRP5/6), receptor-like tyrosine kinase (RYK) and receptor tyrosine-kinase like orphan receptors (ROR) 1 and 2 [8, 9]. These co-receptors are important to regulate downstream signaling either through LRP5/6 co-receptors for the β -catenin dependent or through RYK/ROR1/2 for the β -catenin independent pathway.

Wnt Biosynthesis and Regulation

During its synthesis, Wnt has to undergo a palmitoylation step catalyzed by Porcupine (PORCN), which belongs to the membrane-associated O-acyltransferase family [10, 11]. This step is required for the interaction with Fzd receptors and promotes interaction with the multi-pass transmembrane protein, Wntless, which transports Wnt to the plasma membrane. Since PORCN is required for Wnt secretion, several small molecules have been developed to target it. There are 10 Wnt antagonists that also help mediate Wnt signaling. These antagonists include the secreted Fzd-related proteins (SFRPs), Wnt-inhibitory factor 1 (WIF-1), Wise/SOST, Dickkopf proteins (DKKs), insulin-like growth factor binding protein 4 (IGFBP4), Cereberus, Shisa, Wnt-activated inhibitory factor 1 (Wain1/5 T4), adenomatous polyposis coli down regulated 1 (APCDD1) and Tikil [9, 12]. Several of these regulatory factors have potential as therapeutic targets, but so far, only DKK1 has been evaluated clinically for drug development [13]. The challenge in using these regulatory proteins as targets is that they often regulate the activity of other important cellular pathways. For instance, SFRPs and WIF-1 can bind to Wnt in both canonical and non-canonical signaling depending on the cellular need. SFRPs, however, also regulates the Notch and Bone Morphogenic Protein (BMP) signaling cascade, a key developmental pathway [12, 14].

TYPES OF PATHWAYS

The Canonical Wnt Signaling Pathway in Breast Cancer

Canonical Wnt signaling plays an important role in cell fate decisions in early embryogenesis during the development of organs, such as the lungs, kidney, skin, and bone [8]. This pathway is also critical in neural patterning and stem cell renewal [15]. Canonical Wnt signaling is also called the β -catenin dependent pathway as it results in an accumulation of cytoplasmic β -catenin followed by the latter's translocation to the nucleus [8, 15, 16]. Genetic and biochemical evidence suggests that Wnt binds to Fzd receptors, which have seven transmembrane receptors with a cysteine-rich domain at the N-terminal. Fzd is required for multiple Wnt pathways, but another single-pass transmembrane receptor, LRP6/5 is specifically required for the Wnt/ β -catenin canonical pathway [17].

Canonical Wnt signaling results in stabilization and nuclear translocation of β -catenin [18, 19], which is degraded by a destruction complex consisting of AXIN, Protein phosphatase 2A (PP2A), Casein Kinase 1 α (CK1 α), and Glycogen synthase kinase 3 (GSK3) [19, 20]. In the absence of Wnt, this destruction complex phosphorylates β -catenin, tagging it for ubiquitination and subsequent degradation by the proteasome. Wnt ligands, when bound to the Fzd receptor and the LRP 5/6 transmembrane co-receptor, trigger the recruitment of Disheveled (Dvl) to the plasma membrane [8, 21 - 24]. AXIN is also recruited to the phosphorylated cytoplasmic tail of LRP5/6 [17, 25]. Dvl forms a complex with AXIN, Fzd, and LRP5/6 [26]. Recruitment of AXIN and Dvl prevents the formation of the destruction complex leading to the stabilization of cytoplasmic β -catenin [18, 19]. Dvl proteins also assemble the signalosome that is responsible for phosphorylation of multiple motifs of LRP5/6, one of which is phosphorylated-PPPSPXS/T. P-PPPSPXS/T acts as a competitive inhibitor of GSK3 [26], a kinase that phosphorylates and tags β -catenin for degradation. The net result of these events is the accumulation of unphosphorylated β -catenin resulting in its stabilization. The stabilized β -catenin translocates to the nucleus, where it acts as a transcriptional co-activator in combination with the T-cell factor (TCF) and the lymphoid enhancer-binding factor (LEF) family of transcription factors. This leads to the recruitment of transcriptional Kat3 co-activators p300 and CREB binding protein (CBP) to transcribe Wnt target genes (Fig. 1A) [27]. β -catenin can also interact with other transcriptional co-activators, including BRG-1, a component of the SWI/SNF nuclear remodeling complex, Hsp90 co-chaperone Cdc37, and C-terminal-binding protein (CtBP) [28 - 31]. In the absence of Wnt signaling and nuclear β -catenin, TCF forms a complex with Groucho proteins to recruit histone deacetylases (HDACs) and repress the transcription of Wnt target genes [32 - 34].

CHAPTER 2**CXCR4 Signaling and its Impact on Tumor Progression and Metastasis in Breast Cancer****Dayanidhi Raman***, Cory M. Howard, Sangita Sridharan and Augustus M.C. Tilley*Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, OH, USA*

Abstract: CXCR4 is a G_i-coupled chemokine receptor involved in chemotaxis (directed migration) of tumor and stromal cells into the primary tumor and the pro-metastatic niche that are enriched in CXCL12. In breast cancer, cell surface CXCR4 levels and activity are upregulated and play an important role in local invasion and metastasis. During cancer progression, the CXCL12-CXCR4 axis orchestrates infiltration of endothelial cells and a variety of leukocytes to drive an immunosuppressive tumor microenvironment (TME). When CXCL12 from the TME activates plasma membrane-resident CXCR4 in tumor and stromal cells, a variety of pathways are activated involving signaling modules such as PI3K-AKT, MEK-ERK, and c-Src-p130CAS-paxillin. This triggers a wide variety of cellular processes that drive breast cancer progression, chemoresistance, and metastasis. This provides an opportunity to intervene and target these signaling axes or nodes in clinical trials to antagonize tumor growth metastasis. Finally, careful selection of targeted therapies in combination with the standard of care therapy should be selected judiciously for each patient (precision medicine) with the aim of improving the longevity with minimal toxicity to metastatic breast cancer patients.

Keywords: Breast Cancer, CXCR4, Metastasis, Signaling, Tumor Progression.

INTRODUCTION

Longitudinal exposure to noxious agents such as non-infectious (environmental toxins, food additives, oxidative stress), infectious factors (certain bacteria and viruses), and infestations (parasites) contribute to chronic inflammation. The chronic inflammation is accompanied by the presence of pro-inflammatory cytokines such as interleukins [IL-1 α / β [1], IL-6], interferons (IFN- α), and tumor necrosis factor- α (TNF- α) [2 - 4]. These cytokines trigger the release of chemotactic cytokines or chemokines and the unresolved chronic inflammation

* **Corresponding author Dayanidhi Raman:** Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, OH, USA; Tel: 419-383-4616, Fax: 419-383-6228 18; E-mail: dayanidhi.raman@utoledo.edu

leads to the formation of a neoplastic foci. Chemokines are a family of small molecules (8-12 kDa) that have the ability to facilitate survival, proliferation, migration, local invasion, and eventually metastasis of the breast cancer cells to distant organs. This is important as it is the metastasis that is lethal and not the primary breast tumor. The intra- and inter-tumor heterogeneity observed in breast cancer supports tumor progression and facilitates metastasis. The stromal cells along with acellular matrices form the tumor microenvironment (TME) [5,6]. The stromal TME plays a key role in orchestrating tumor progression and also contributes to chemoresistance. Importantly, chemokines secreted into the TME recruits the pro-tumor stromal cells such as M2-like macrophages [7], N2 neutrophils [8 - 10], myeloid-derived suppressor cells (MDSCs) [11,12], endothelial progenitor cells (EPCs) [13], adipocytes, and endothelial cells [14]. The recruited and subverted stromal cells secrete many cytokines, chemokines and growth factors such as IL-6, CXCL8, CXCL12, and vascular endothelial growth factor (VEGF). They also secrete extracellular matrix proteins such as tenascin-C, collagen I, and matrix metalloproteinases (MMPs). This facilitates autocrine and paracrine signaling in the TME-resident tumor and stromal cells which recruits additional pro-tumorigenic cells to the developing TME. Carcinoma-associated fibroblasts (CAFs) are already present around the tumor cells and support tumor growth, chemoresistance, and metastasis [15 - 17]. The acellular matrix provides a desmoplastic microenvironment that makes the tumor denser and renders them more chemoresistant. Thus, the paracrine interactions between the breast cancer cells with the tumor-educated stromal cells facilitate all stages of breast cancer progression, survival, angiogenesis, and metastasis (Fig. 1). The CXCL12-CXCR4 axis is intricately involved in many of these steps of tumorigenesis and metastasis.

CXCL12-CXCR4 AXIS

The chemokine stromal-derived factor-1 α (SDF-1 α) or CXCL12 is the ligand for the heterotrimeric, seven transmembrane G-protein coupled receptor (GPCR) CXCR4. There are six alternatively spliced isoforms of CXCL12 that have been identified [18]. CXCL12- α is made of 89 amino acid residues while CXCL12- β contains an additional four amino acid residues at the C-terminus [19]. The ligands, CXCL12- α and CXCL12- β , bind with comparable affinity to CXCR4 receptor (K_d of 7.5 and 13.7 nM, respectively) [20]. Four additional splice variants (CXCL12- γ , CXCL12- δ , CXCL12- ϵ , and CXCL12- Φ) have been identified that contain 30 additional amino acid residues at their C-termini as compared to CXCL12- α [21]. All of these isoforms are functional and have a differential tissue distribution, but CXCL12- α is the predominantly expressed form. CXCL12- γ has been detected in patients with advanced disease (stage IV) at the mRNA level

[22]. The cell migration induced by CXCL12- γ showed resistance to inhibition by common CXCR4 antagonists [22].




Fig. (1). Understanding the role of the heterogeneous breast tumor and the CXCL12-CXCR4 axis in the metastatic breast cancer cascade. The CXCL12 enriched microenvironment in distant organs such as the bone, lungs, liver or brain facilitates the metastatic spread of breast cancer cells expressing the cell surface CXCR4.

The CXCL12-CXCR4 axis is highly involved in primary tumor progression and metastasis in breast cancer [23 - 25]. Upon binding of CXCL12 to CXCR4, the receptor gets activated and triggers conformational changes in the heterotrimeric G-protein ($G\alpha\beta\gamma$, pertussis toxin-sensitive) initiating several divergent network of signaling pathways in breast cancer cells. Activation of CXCR4 signaling facilitates increase in intracellular calcium, cell survival and proliferation, gene transcription, cell adhesion, directional cell migration (chemotaxis), local invasion and metastasis [26 - 29]. Among them, the phosphatidylinositol 3'-kinase (PI3K), mitogen-activated protein kinase (MAPK), and *c-Src* signaling pathways tremendously contribute to tumorigenesis and subsequent metastasis [30] (Fig. 2). CXCR4 also couples with $G\alpha_{13}$ to facilitate Rho GTPase-mediated transendothelial migration of basal-like breast cancer cells [31,32]

Epidermal Growth Factor Receptor Signaling in Colon Cancer

Avtar S. Meena^{1,*} and Pradeep K. Shukla^{2,*}

¹ CSIR-Centre for Cellular and Molecular Biology (CCMB) Habsiguda, Uppal Road Hyderabad - 500 007 Telangana, India

² Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA

Abstract: Epidermal growth factor receptor (EGFR) expression regulates cancer cell proliferation, survival, and metastatic potential and is associated with the majority of human carcinomas, including colorectal carcinoma. The relationship between EGFR expression and its prognosis in cancer patients, however, has not been proven in clinical settings. Various preclinical studies suggest that the oncogenic potential of EGFR is associated with levels of EGFR ligands. Mutations in EGFR family ligands and their receptors are characteristic of many different kinds of tumors. Therefore, this signaling axis is an attractive target for the development of targeted therapies. Various small molecule inhibitors and antibodies are in clinical trials that specifically target EGFR.

Here, we will discuss the current literature's attempts to identify markers, which contribute resistance and sensitivity to small molecule EGFR inhibitors. Moreover, we will summarize the role of EGFR in the development of colon cancer. We will discuss the mechanistic basis for EGFR interaction with various molecules, its consequences for biology, and its prospective importance as a target for colon cancer therapy.

Keywords: Cancer therapy, Cancer cell proliferation, Colon cancer, EGFR ligands, Epidermal growth factor receptor (EGFR), Targeted therapies.

COLORECTAL CANCER AND RISK FACTORS

Colorectal cancer (CRC) is the second most prevalent human malignant disease. It is one of the prominent causes of cancer-related mortalities globally [1]. The development of CRC comprises a complex multistage process in which sequential

* **Corresponding authors Pradeep K. Shukla and Avtar S. Meena:** Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Tel: 38163-2113; (901) 448-3019 and CSIR-Centre for Cellular and Molecular Biology (CCMB), Habsiguda, Uppal Road, Hyderabad-500007 Telangana, India; Tel: +91-40-27160222; E-mails: pshukla2@uthsc.edu and avtarsingh@ccmb.res.in, respectively

mutational events occur along with the progression of cancer. The 5 -year survival of patients diagnosed with metastatic colorectal cancer (mCRC) is approximately 13-18%. Early detection and treatments are essential for the prevention of colon cancer-related death. Approximately 60-80% of CRC patients exhibit overexpression of EGFR, which is associated with poor prognosis [2]. Various treatment agents have recently been established to demonstrate prominent efficacy in the treatment of mCRC.

For this reason, EGFR has been the central target for treatment with small-molecule inhibitor and monoclonal antibodies, cetuximab and panitumumab, which have been useful for patients with RAS wild type in randomized clinical trials [3 - 5]. There are multiple significant risk factors for the development of CRC, which are crucial for an increase in the rate of genetic mutation occurring in tumor suppressor genes and various oncogenes as well. These factors generally include environmental exposure, personal or family history of CRC, genetic mutation, location, and associated disease(s). Environmental exposures such as smoking, alcohol use, sedentary lifestyle, diet, and abdominal radiation are associated with an increased risk of CRC [6 - 12]. Supplementation of a high-fat Western diet promotes the development of colon cancer *via* an EGFR mediated mechanism [13]. Various habits or personal behaviors are major risk factors for the development of colorectal cancer (CRC). As with many cancers, the risk of CRC increases with age without gender differences [14]. Other than the age, people who have diabetes, obesity, and inflammatory bowel disease (IBD) are at higher risk of developing CRC, respectively [15 - 17]. We will discuss EGFR signaling, the development of anti-EGFR therapies, and mechanisms of resistance to EGFR therapies in CRC.

EGFR SIGNALING IN CRC

EGFR is one of the crucial targets to be exploited in cancer treatment, including CRC. The receptor, which belongs to the receptor tyrosine kinase (RTK) family, also known as HER1 (human EGFR receptor), is a 170-kDa transmembrane protein that acts as a receptor for the EGF family. In addition to EGFR, the receptors belonging to the RTK superfamily are ErbB- 2 (HER/c-neu), ErbB-3 (Her 3), and ErbB-4 (Her 4). All of these receptors are composed of an extracellular ligand-binding domain (cysteine-rich domain), a hydrophobic transmembrane region, a short juxta-membrane section, and an intracytoplasmic tyrosine kinase C-terminal domain (Fig. 1A). EGFR and ErbB4 receptor exhibit a similar structure and are involved in ligand-dependent homo- or heterodimerization. In contrast, erbB2 lacks a ligand-binding domain and has been shown to elicit both ligand-dependent and independent dimerization [18, 19]. ErbB3 also undergoes ligand-dependent dimerization; however, these receptors have been

shown defective in their intrinsic tyrosine kinase activities. Therefore, they require heterodimerization with another member of the erbB family for the activation of signaling cascade [20]. Autophosphorylation of one intracellular kinase domain by the others promotes downstream signaling cascades. In general, there are seven combinations of receptor dimers and ten ligands binding partners that play a crucial role in the activation of downstream signaling cascade [21]. Various combinations of receptors and their ligands involved in signaling pathways summarized in Fig. (1B) and (1C). EGFR is expressed on all stromal and epithelial cells and is presented on various glial and smooth muscle cells as well [22]. Because of its involvement in cancers, EGFR has been a focus for the development of drug targets. Multiple studies suggest the role of EGFR in neoplastic progression. Three crucial mechanisms have been documented so far. First, a mutation in the EGFR gene, which leads to its constitutive activation even in the absence of ligand [23, 24]. Second, increased EGFR expression in breast, non-small cell lung, and colon cancer [25, 26]. However, it has remained unclear whether increased expression correlated with oncogenic activity. Third, EGFR signaling involves the binding of specific soluble ligands (*e.g.*, EGF, amphiregulin, epiregulin, betacellulin, or neuregulin), and mediate downstream signaling. Downstream signaling regulates cellular activities, including cell growth, survival, proliferation, inhibition of apoptosis, and differentiation in mammalian cells [27]. Binding of ligand to EGFR induces conformational changes in the receptor that promotes homo- or heterodimer formation between receptors. Receptor dimerization is crucial for the activation of intracellular tyrosine kinase and phosphorylation of the C-terminal domains, which provide a docking site for cytoplasmic proteins harboring phosphotyrosine-binding and Src homology-2 domains [28]. EGFR family activates Ras/Raf/MEK/MAPK, PLC γ -1/PKC, phosphatidylinositol-3 kinase/Akt, and STAT pathways (Fig. 2). In the next section, we will discuss the role of the EGF-like growth factors, MAPK, and PI3K/ Akt signaling pathways, which have pivotal roles in CRC development and progression (Fig. 2). Moreover, various signaling molecules and their mutation status involved in CRC progression are summarized in Table 1.

Table 1. Summary of Signaling pathways altered in CRC.

Gene	Protein Function	Observed Alteration	Mutation	Ref.
<i>EGFR</i>	Transmembrane tyrosine kinase receptor	Mutation	Very Rare	[42]
		Protein Expression	30-90%	[148]
		Increased Copy Number	0-50%	[149]
<i>KRAS</i>	GDP/GTP binding protein facilitates EGFR downstream signaling	Activating Mutation	35-40%	[112, 113, 150]

CHAPTER 4**Targeting the PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma: Current State and Future Trends****Neelam Yadav*** and **Yoganchal Mishra¹**¹ *Department of Biochemistry, Dr. Rammanohar Lohia Avadh University, Faizabad-224001, India*

Abstract: Hepatocellular carcinoma (HCC) is the most common liver cancer and the leading cause of cancer-related deaths. Advanced HCC has a poor prognosis with limited treatment option. Chronic liver diseases and cirrhosis are the main risk factors for the development of HCC. Phosphoinositide 3-kinase PI3K/AKT/mTOR, intracellular mediators play a very important role in the development and progression of HCC. This signaling pathway is frequently activated in HCC patients. Therefore, signaling pathways have become the main source of targets for new treatments in HCC patients.

In our chapter, we will discuss the role of PI3K/AKT/mTOR signaling pathway in the pathology of HCC and provide an update on the preclinical and clinical approaches for the development of various molecular agents targeting this proliferation/survival pathway, which include various PI3K/Akt/mTOR inhibitors and other agents for the treatment of HCC.

Keywords: Hepatocellular carcinoma, Inhibitors, Signaling pathways, Sorafenib, Therapy.

INTRODUCTION

Hepatocellular carcinoma (HCC) is an aggressive tumor of the liver and the third most common cause of death in human beings [1, 2]. Its poor prognosis is due to relapse and metastasis [3 - 5]. In HCC patients, metastasis is an essential cause of high mortality [6 - 8]. Ji *et al.* [9], reported that the clinical diagnosis and treatment of HCC patients have made great progress in the last few years. HCC occurs mainly in patients suffering with chronic liver disease and cirrhosis. Most of the mortality in HCC patients results from liver cirrhosis related problems like ascites, hepatic encephalopathy, hepatorenal syndrome and variceal hemorrhage.

* **Corresponding author Neelam Yadav:** Department of Biochemistry, Dr. Rammanohar Lohia Avadh University, Faizabad-224001, India; Tel: +91 9453731722; neelam2k4@gmail.com

Several genes are responsible for the tumorigenesis and progression of HCC and many molecular changes play a crucial role in the development of this aggressive malignancy [10, 11].

Due to the activation of many signal transduction pathways that regulate cell proliferation and tumor progression and complex molecular alteration in hepatic tissue, treatment of HCC is not successful [12]. The phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway is repeatedly activated in HCC.

Many patients with HCC are diagnosed at the advanced stage of the disease. Current treatment therapies for HCC are locoregional ablative approaches, surgical removal and interventional ablation techniques. Although these treatments could increase few year's survival rate in 70% patients of HCC, however, long-term survival remains low due to the high rate of recurrence and metastasis after surgical resection [13 - 15]. Therefore, novel evidence-based therapies for this aggressive malignancy is urgently needed.

Risk Factors for HCC

In HCC patients, no early noticeable symptoms appear during tumor development. Its occurrence is associated mainly with aflatoxin B1 contaminated food and endemic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, obesity and non-alcoholic steatohepatitis. Despite the food storage conditions and implementation of vaccinations to reduce the risk of aflatoxin B1 and contamination and hepatitis B infection respectively, the incidence of liver cancer is not decreasing. Early risk factors responsible for the development of HCC are immune-mediated chronic inflammation in hepatitis that results into progressive fibrosis and development of liver cirrhosis [16, 17].

Pathophysiology

The development of hepatocellular carcinoma is a complex process that involves many steps. It mainly occurs after liver cirrhosis and is associated with the diversity of aetiologies of the major chronic liver disease. In liver cirrhosis, HCC follows a sequence of events that involves pre-cancerous cirrhotic nodules development known as low-grade dysplastic nodules (LGDNs). High-grade dysplastic nodules (HGDNs) develop from LGDNs and convert into early-stage HCC and then more advanced HCC. Various cells, including mature hepatocytes and stem or progenitor cells, play an important role in malignant transformation into HCC [18]. The accumulation of somatic genomic alterations in driver and passenger cancer genes is responsible for HCC. However, genomic alterations are not accumulated, which suggests that many signaling pathways may involve in the promotion of carcinogenesis [19].

In HCC progression, several pathways and processes have been involved (Table 1). A number of epigenetic and genetic changes like rearrangements and deletions of chromosomes, mutations, aneuploidy, gene amplification, and DNA methylations have been observed in HCC.

Table 1. Major gene alterations reported in advanced hepatocellular carcinoma.

Name of Pathway(s)	Gene(s) Name	Type of Alteration	Frequency Percentage (%) in HCC
AKT–mTOR– MAPK signalling	PTEN	Mutation or deletion	1-3%
	RPS6KA3	Mutation	2-9%
	TSC1 and TSC2	Mutation or deletion	3-8%
	FGF3, FGF4 and FGF19	Amplification	4-6%
	P13KCA	Mutation	0-2%
WNT-β– catenin signalling	AXIN1	Mutation or deletion	5-15%
	CTNNB1	Mutation	11-37%
Angiogenesis	VEGFA	Amplification	3-7%
Oxidative stress	KEAP1	Mutation	2-8%
	NFE2L2	Mutation	3-6%
Telomere maintenance	TERT	Amplification	5-6%
		Promoter mutation	54-60%
Cell cycle control	RB1	Deletion or Mutation	3-8%
	CCND1	Amplification	7%
	TP53	Mutation or Deletion	12-48%
	CDKN2A	Mutation or Deletion	2-12%

AXIN1, axin 1; *CCND1*, cyclin D1; *CDKN2A*, cyclin-dependent kinase inhibitor 2A; *CTNNB1*, β-catenin; *FGF*, fibroblast growth factor; *KEAP1*, kelch like ECH associated protein 1; *NFE2L2*, nuclear factor, *PI3K*, phosphoinositide 3-kinase; *PTEN*, phosphatase and tensin homologue; *RB1*, retinoblastoma 1; *RPS6KA3*, ribosomal protein S6 kinase, 90kDa *TSC*, tuberous sclerosis; *TERT*, telomerase reverse transcriptase; *TP53*, cellular tumor antigen p53; *VEGFA*, vascular endothelial growth factor A.

Basic Signaling Pathways

Llovet *et al.* [20], reported that the oxidative stress, chromatin remodeling, Wnt/ beta catenin and other signaling pathways including epidermal growth factor (EGF), insulin growth factor, vascular endothelial growth factor (VEGF), fibroblast-derived growth factor (FGF), platelet-derived growth factor (PDGF), and intracellular mediators RAS–RAF–MAPK (MAP kinase) and PI3/AKT are critical signaling pathways in HCC (Table 1).

Many growth factors signaling (IGF, EGF, PDGF, FGF, and HGF), angiogenesis (VEGF) and cell differentiation (*e.g.*, WNT, Hedgehog, Notch) modules are de-

CHAPTER 5**MAPK Signaling Pathway: A Central Target in Pancreatic Cancer Therapeutics****Sahdeo Prasad and Sanjay K. Srivastava****Department of Immunotherapeutics and Biotechnology, and Center for Tumor Immunology and Targeted Cancer Therapy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA*

Abstract: Pancreatic cancer remains one of the most clinically challenging cancer despite the advancement in molecular characterization of this disease. Malignancy of this disease is characterized by the constitutively activated mitogen-activated protein kinase (MAPK) pathway. The MAPK pathway is activated by growth factors, mitogens, hormones, cytokines and environmental factors. Activated MAPK induces expression of downstream genes and regulates cell proliferation, survival, differentiation, motility, receptor signaling, senescence and transport. Activation of MAPK in pancreatic cancer is associated with a poor prognosis and results in limited treatment options. This poor prognosis elicits a need for the development of effective therapeutic measures to treat and improve pancreatic cancer patient survival. MAPK targeted pancreatic cancer therapy has been developed in the last few decades with the use of a number of inhibitors. Inhibitors of RAS, MEK1/2 and ERK1/2 are the main drugs used pre-clinically and in clinical settings of pancreatic cancer treatment. Although these inhibitors have shown some clinical benefits, extensive research on the development of new MAPK signaling pathway inhibitors for the treatment of pancreatic cancer is warranted.

Keywords: Inhibitors, MAPK, Pancreatic cancer, Targeted therapy.

INTRODUCTION

Pancreatic cancer is the fourth leading cause of cancer-related deaths and one of the most lethal malignant neoplasms across the world. According to the American Cancer Society, about 55,770 people will be diagnosed with pancreatic cancer and about 45,750 people will die in 2019. Pancreatic cancer accounts for about 7% of all cancer deaths in the USA and about 3% of all cancers. The 5-year survival rate of people with pancreatic cancer is also very low (8%). Incidence rates are also observed 25% higher in black people than in white people. Although tremendous

* **Corresponding author Sanjay K. Srivastava:** Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Suite 1305, 1718 Pine Street, Abilene, Texas 79601 USA; Tel: 325-696-0464; E-mail: sanjay.srivastava@ttuhsc.edu

efforts have been made to improve therapeutic intervention, the prognosis remains poor because the diagnosis of pancreatic cancer at an early stage is very difficult due to the lack of specificity and cost-effective screening tests. This cancer is usually diagnosed at an advanced stage and is also resistant to chemotherapy [1]. Despite the recent advancement in therapeutic techniques and medical management, the median survival time of pancreatic cancer patients is only 5-8 months because of tumor cell invasion, early metastasis, and resistance to standard chemotherapy.

This poor prognosis, metastasis and resistance to therapy lead to target specific molecules for effective therapy and improvement of pancreatic patient survival. Advanced studies are needed to understand the pathogenesis, signaling network and molecular targets that may provide clues for the treatment of pancreatic cancer. Although pancreatic cancer is a multifactorial disease, the mitogen-activated protein kinase (MAPK) pathway is found to be constitutively activated in this cancer. In this chapter, the relevance and mechanism of MAPK activation in the pathobiology of pancreatic cancer will be explored. The therapeutic approach of pancreatic cancer by targeting MAPK will also be discussed.

Activation of the MAPK Pathway

MAPK proteins are Ser/Thr kinases, which coordinately regulate signal transduction, cell division, proliferation, gene expression, metabolism, motility, transport, survival, apoptosis, and differentiation. Typically MAPKs include the extracellular signal-regulated kinases 1/2 (ERK1/2), c-Jun amino (N)-terminal kinases 1/2/3 (JNK1/2/3), p38 [2 - 4], but recent studies suggest that atypically ERK3/4, ERK5, ERK7, and nemo-like kinase (NLK) are also included [5]. ERK, JNK, and p38 isoforms are known to form a group based on their activation motif, structure and function [6]. p38 MAPK is classified into four types such as p38 α , p38 β , p38 γ , and p38 δ [7].

MAPKs consist of three sets of kinases including MAPK, MAPK kinase (MAPKK), and MAPKK kinase (MAPKKK). It has been found that the canonical MAPK/ERK pathway is composed of three types of MAPKKK that include A-RAF, B-RAF and RAF-1 or C-RAF kinases while MAPKK is composed of MAPK/ERK kinase (MEK)1 and MEK2. ERK1 and ERK2 are the downstream kinases and are the final effectors of the MAPK pathway [8]. MAPK is activated by a broad range of stimuli such as mitogens, growth factors, cytokines, environmental and other factors. Besides these, other factors such as chemokines, microRNA, kinases, and other proteins are associated with the activation of the MAPK signaling pathway (Fig. 1). These stimuli first activate MAPKKK, which are protein Ser/Thr kinases, by phosphorylation. The activation of MAPKKK

occurs *via* receptor-dependent and -independent mechanisms. In receptor-dependent mechanism, activation is initiated by the binding of an inducing ligand to the receptor tyrosine kinase (RTK) residing on the plasma membrane of the cells, which leads to the activation of RAS G-protein. In turn, RAS recruits and activates the serine/threonine protein kinase, RAF, a MAPKKK [9]. The activated MAPKKK phosphorylates and activates its downstream kinase MAPKK, which in turn phosphorylates Thr and Tyr residues and activates MAPKs. Activation of MAPKs further leads to the activation of specific MAPK-activated protein kinases (MAPKAPKs). The activation of MAPKAPKs results in a broad range of fundamental cellular activities including stress response, growth, proliferation, differentiation, survival, motility and apoptosis. However, events of MAPK phosphorylation are found to be inactivated by MAPK protein phosphatases (MKPs) that dephosphorylate both threonine and tyrosine residues on MAPKs [10].




Fig. (1). Activators and inhibitors of the MAPK signaling pathway.

Role of NF- κ B Activation in Multiple Myeloma and Other Hematological Malignancies

Loukik Arora¹, Frank Arfuso², Alan Prem Kumar¹ and Gautam Sethi^{1,*}

¹ Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

² Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Australia

Abstract: NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) is a rapid-acting transcription factor. It is present in almost all cell types and is one of the primary responders to several stimuli such as stress, cytokines, radiation, chemotherapeutic drugs, bacterial, and viral antigens. Aberrant regulation and activation of NF- κ B have been implicated in several cancers, inflammatory and autoimmune disorders, viral infections, and erroneous immune system development. This chapter summarizes the role of NF- κ B activation specifically in hematological malignancies and various strategies developed for its potential pharmacological intervention to abrogate the process of carcinogenesis.

Keywords: Leukemia, Lymphoma, Myeloma, NF- κ B, IKKs.

INTRODUCTION

NF- κ B (Nuclear factor kappa-light-chain-enhancer of B cells) is a nucleocytoplasmic protein complex involved in controlling transcription, production of cytokines, and regulating cell survival [1 - 5]. NF- κ B is ubiquitously present in almost all human tissue types and responds to various stress stimuli such as cytokines, growth factors, radiation, oxidative stress, free radicals, *etc.* It also plays an important role in regulating the immune response to infections [2, 6 - 8]. Five members have discovered and classified in the mammalian NF- κ B family so far. They are NF- κ B1 NF- κ B2, Rel A, Rel B, and c-Rel [9 - 11] (Table 1). Fig. (1) shows the downstream target genes modulated by NF- κ B to regulate a myriad of cellular responses.

* Corresponding author **Gautam Sethi:** Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600; Tel: +65 65163267; Fax: +65 68737690; Email: phcgs@nus.edu.sg

Table 1. Human NF-κB proteins.

Class	Protein	Gene
Class I	NF-κB1 (p50)	<i>NFKB1</i>
	NF-κB2 (p52)	<i>NFKB2</i>
Class II	RelA (p65)	<i>RELA</i>
	RelB	<i>RELB</i>
	c-Rel	<i>REL</i>

Theoretically, about 15 unique homo- and heterodimer combinations can be derived from the dimerization of five NF-κB subunits; of which 12 have been identified *in vivo*. The interactions between these subunits are based on the general principles of interaction between protein-protein complexes and this explains why RelA-p50 and RelB-p52 can form the most stable dimers among 12 of them [12].




Fig. (1). A list of selected genes regulated by transcription factor NF-κB.

STRUCTURE AND SIGNALING CASCADE OF NF-κB PROTEINS

NF-κB Activation and Signaling

NF-κBs are classified as rapid-acting transcription factors; *i.e.* they are present in the cell in an inactive state and are not dependent on *de novo* protein synthesis for

their activation [13 - 15]. The NF- κ B pathway can be primarily activated by two different processes, namely the canonical/classical pathway and the non-canonical pathway [16, 17] as briefly summarized in Fig. (2).




Fig. (2). A schematic representation of canonical and non-canonical NF- κ B activation pathways.

Canonical or Classical Pathway

In the resting or unstimulated cell, the NF- κ B heterodimer (RelA-p50) are sequestered in the cytoplasm as the nuclear localisation signal is masked by Inhibitors of κ B (I κ B). In canonical signaling, the ligand binding (cytokines, growth factors, lipopolysaccharides) to their respective receptors can induce the phosphorylation of the IKK (I κ B Kinase) complex, which consists of IKK α , IKK β , and NF- κ B essential modulator (NEMO). The phosphorylation of IKKs leads them to phosphorylate I κ B α . The phosphorylated I κ B α after ubiquitination, undergoes proteasomal degradation, thereby freeing the p50-RelA heterodimer. This heterodimer translocates to the nucleus and initiates the transcription of NF- κ B downstream effector genes [18]. It has been found that ubiquitination can activate NF- κ B pathway independent of the proteasome. As the regulator of IKK complex, NEMO has been suggested to modulate this proteasome independent ubiquitination mediated by K63 polyubiquitin chains [19].

CHAPTER 7

Bruton's Tyrosine Kinase Signaling and Advancement in Multiple Myeloma Therapy

Krishne Gowda^{1,*}, Max Von Suskil², Omar S. Al-Odat², Jennifer Dang², Kuntal Bhowmick², Prachi S. Narayan², Shantu G Amin¹ and Manoj K. Pandey^{2,*}

¹ Department Pharmacology, Penn State College of Medicine, Hershey, PA, USA

² Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA

Abstract: The Bruton's tyrosine kinase (BTK) is a non-receptor protein-tyrosine kinase (PTK) required for the growth and differentiation of B-lymphocytes, which play a critical role in the progression of numerous neoplasms. Therefore, BTK has emerged as an exciting and attractive target for inhibition of hematological malignancies. Various BTK inhibitors have already proved remarkable tumor suppressing ability in clinical studies. Ibrutinib was the trail blazing BTK inhibitor that first showed exceptional tumor inhibition in patients, this molecule showed excellent response in refractory/relapsed (R/R) conditions with high-risk genetic lesions patients, particularly among chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Based on ibrutinib's efficacy and tolerability, in 2016, the Food and Drug Administration (FDA) approved it as a first-line treatment for CLL patients. Ibrutinib occupies the ATP-binding active site of BTK, making salt bridges within the hinge that connects the two enzyme lobes followed by the unsaturated acrylamide group of ibrutinib covalently bonding with the BTK cysteine 481 residue to irreversibly form an inactive adduct. However, ibrutinib's irreversible binding mechanism leads to acquired resistance to the medication. Both resistance arising due to mutations that impair the affinity of ibrutinib for BTK and the undesirable side effects of the drug have led to the development of numerous second-generation inhibitors. The efficacy and specificity of novel BTK inhibiting agents such as Acalabrutinib, ONO/GS-4059, KS99, and other small molecules have substantiated solutions to ibrutinib's shortcomings. The detailed role of BTK signaling pathways, and its cross-talk between other signaling pathways, the significance of BTK inhibition in hematological malignancies, and the current progress in the discovery of small molecule BTK inhibitors are presented in this chapter.

Keywords: Multiple myeloma, Hematological malignancies, Bruton's tyrosine kinase, Myeloma stem cells, Drug development.

* Corresponding author **Krishne Gowda:** Department Pharmacology, Penn State College of Medicine, Hershey, PA, USA; Tel: 717-531-0003 Ext 285014; Fax: 717-531-0244; E-mail: kxg21@psu.edu

* Corresponding author **Manoj K Pandey:** Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA; Tel: 856-956-2751; E-mail: pandey@rowan.edu

INTRODUCTION

Protein kinases (PKs) are enzymes that regulate the biological activities of proteins through mediating phosphorylation and play an essential role in every aspect of cellular functions [1]. PKs regulate cellular metabolism, transcription, division, migration, and apoptosis, as well as participate in immune responses and nervous system function. Protein phosphorylation involves the balanced action of PKs and phosphatases [2]. Phosphorylation plays a critical role in increasing or decreasing enzyme activities through post-transcriptional modification, thereby controlling signal transduction, gene expression, protein stabilization, enzyme affinity, and cellular location. Thus, the aberrant activation of PKs is associated with various disorders, especially neoplasms [3, 4].

BTK signaling was first discovered as the functional defect in the immune system condition X-linked agammaglobulinemia (XLA) in 1993. People with XLA suffer from marginal populations of B cells due to mutations in the BTK gene preventing either BTK production or function. Following the discovery of BTK in XLA, a number of studies have demonstrated conclusively that BTK is required for B-cell development, differentiation, and survival [5 - 8]. BTK knockdown studies in animal models suggest that B-lymphocytes deficient in BTK showed impaired signal transduction resulting in functional defects, inability to reach a mature state, and ultimately, high rates of apoptosis.

The B cell receptor (BCR) stimulation induces BTK phosphorylation and signal transduction [9, 10]. The BCR is a trans-membrane protein complex comprised of multiple subunits, including an immunoglobulin heavy chain (IgHC) covalently linked by disulfide bonds to an immunoglobulin light chain (IgLC) [11]. The B cell surface expresses BCR, which mediates antigen recognition. Besides the BCR pathway, BTK activation modulates various other receptor pathways vital to B cells, including chemokine-X-chemokine receptors (CXCR4 and CXCR5), toll-like receptor (TLR), and signaling mediated by Fc receptors [12 - 15]. Though in some cell types, such as in myeloid lineages, BTK acts as a downstream target of TLRs, FcεR, and FcγRI signaling pathways [16 - 19]. Furthermore, BTK is shown to be linked in numerous additional signaling pathways, including receptor activator of nuclear factor-κB (RANK) in osteoclasts, collagen/CD32 signaling in platelets, and the NLRP3 (NOD-, LRR- and Pryn Domain-containing protein 3) inflammasome signaling in macrophages and neutrophils [20 - 22]. Based on various scientific reports, it is now established that most hematopoietic cells, including myeloid cells, express BTK, which has created significant interest among drug discovery and development groups in using BTK inhibition as an anti-cancer therapy against various malignancies (Fig. 1) [23 - 25].

This chapter describes the significance of BTK signaling as well as the pathway cross talks. Also, how the small molecule inhibitors have clinical benefits of targeting BTK in B cell malignancies is described.




Fig. (1). The signaling of BTK pathways regulates various intermediate signaling. These signaling pathways individually contribute in the pathogenesis of malignancies.

THE BTK SIGNALING PATHWAY

Structure and Activation of BTK

BTK is one of the five members of TEC (Tec protein tyrosine kinase) family and consists of 659 amino acid residues [10]. The BTK domain structure is similar to that of the SRC family kinases in containing a C-terminal catalytic domain and the SRC homology domains (SH2 and SH3] (Fig. 2). As compared to SRC, BTK lacks a negative regulatory tyrosine residue at the C-terminal and an N-terminal myristoylation signal [10]. Instead, BTK contains a proline-rich TEC homology (TH) domain and an N-terminal pleckstrin homology (PH) domain, which

CHAPTER 8

The Tumor Microenvironment Mediated Signaling Pathways in the Progression of Acute Myeloid Leukemia

Anup S. Pathania¹, Rachel Weber² and Kishore B. Challagundla^{1,3,*}

¹ Department of Biochemistry and Molecular Biology & The Fred and Pamela Buffett Cancer Center; University of Nebraska Medical Center, Omaha, NE, USA

² Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

³ The Children's Health Research Institute, University of Nebraska Medical Center, Omaha, NE, USA

Abstract: Acute myeloid leukemia (AML) is a cancer of blood and bone marrow, caused by abnormal production of white blood cells. According to the recent 2020 statistics, an estimated number of 19,940 people in the United States will be diagnosed with AML. The hematologic tumor microenvironment plays a critical role in the progression of AML. Emerging evidence indicates that chemotherapy resistance and disease relapse are linked through the signaling pathways associated with the tumor microenvironment in AML. The leukemia cells communicate with the other non-cancerous cells of the tumor microenvironment through small vesicles that are within the size of 30-120nm called exosomes, a type of extracellular vesicles. Exosomes contain genetic information in their cargo, in the form of either protein, DNA, or non-coding RNAs and communicate to the distinct cells through various signaling pathways. The c-Myc oncogenic transcription factor protein is a master regulator of oncogenic signaling pathways in various cancers, including AML. C-Myc has been associated with the development of therapy resistance in AML, representing a key target. The interconnection between exosomes, tumor microenvironment, c-Myc and the development of progression, therapy resistance are discussed in this chapter and thus, represents a fundamental knowledge of the recent advances in cancer signal transduction and therapy.

Keywords: Acute myeloid leukemia, C-Myc, Drug resistance, Exosomes, Oncogene, Tumor microenvironment, Tumor suppressor gene.

* Correspondence author **Kishore B. Challagundla**: Department of Biochemistry & Molecular Biology, The Fred and Pamela Buffet Cancer Center, FPBCC 6.12.320, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, NE 68198-5870, USA; Tel: 402.559.9032; Fax: 402.559.6650; E-mail: kishore.challagundla@unmc.edu

Anup S. Pathania & Rachel Weber share equal contribution

INTRODUCTION

Leukemia is a type of cancer that forms in the blood and is typically characterized by an abnormal number of aberrant leukocytes. The bone marrow and lymphatic system are affected as that are where white blood cells are produced and found after maturation. Leukemia made up 30.4% of all blood cancers in 2017 and accounts for 2.9% of cancer cases overall [1]. This cancer is divided into two categories: acute and chronic. From there, it can be separated into subcategories based on the cell it affects, myeloid or lymphocytic. The five main types are acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) [2]. Leukemia is the highest occurring cancer in children, with ALL making up the majority and AML is the second most common [3]. Acute leukemias tend to affect pediatric patients, whereas adults are more often seen with chronic leukemia. Major risk factors include smoking, family history, genetic disorders, exposure to chemicals, and other environmental factors [4, 5]. Chemotherapy, radiation, or bone marrow transplantation are typical treatment options, although most of these therapies are used in conjunction with another [6]. Cancer type and patient age affect the outcome of the treatment. It can be unsuccessful due to the leukemia cells communicating with the bone marrow microenvironment they reside in. During this exchange, cancer cells are able to develop the ability of self-renewal and chemoresistance [7 - 9]. Bone marrow is where hematopoietic stem cells (HSC) are located, which aids in the stemness of leukemia cells, thus leading to increased resistance to treatment [10, 11].

THE TUMOR MICROENVIRONMENT AND ACUTE MYELOID LEUKEMIA

The microenvironment cells, such as surrounding the blood, and lymph vessels, extracellular matrix, fibroblasts, and tumor-infiltrating immune cells, including B and T lymphocytes, natural killer cells, macrophages, neutrophils, dendritic cells, and mast cells are called tumor microenvironment. The tumor microenvironment plays a crucial role in the initiation and progression of leukemia. Many studies have extensively addressed the role of microenvironment in hematologic malignancies, including AML. One of the examples is retinoic acid receptor γ deficiency in bone marrow microenvironment, which can induce the development of myeloproliferative disorders, a group of slow-growing blood cancers in the bone marrow [12]. The genetic changes in specific mesenchymal cells of the hematopoietic microenvironment can induce myelodysplasia, a condition in which immature blood cells do not mature and later may progress to leukemia. Deletion of *Dicer1*, an RNase III endonuclease essential for miRNA biogenesis and RNA

processing in mesenchymal osteolineage cells, induces myelodysplasia that later progression into AML. The transplantation of hematopoietic cells from *Dicer1* knock out mice into healthy mice does not induce myelodysplastic symptoms. Conversely, transplantation of hematopoietic cells from healthy mice into lethally irradiated mutant mice results in the development of leukemia like symptoms suggesting the role of microenvironment in determining leukemia induction [13]. Moreover, a constitutively active β -catenin mutation in mouse osteoblasts alters differentiation in myeloid and lymphoid progenitors, that can lead to the development of AML. β -catenin is the critical effector molecule that transduces Wnt signaling to the nucleus and activate the transcription of Wnt specific genes involved in cell fate decisions [14].

Transplantation of bone marrow cells from constitutively active β -catenin mice into lethally irradiated wild-type mice induces hematopoietic dysfunction and AML [15]. β -catenin activation in osteoblasts stimulates expression of the Jagged 1, a Notch ligand that contributes to the deregulation of hematopoietic stem cells (HSC) lineage differentiation and AML development. Interestingly, β -catenin mutant and Jagged 1 knockdown mice do not show deregulated hematopoietic differentiation and AML development, suggesting that Notch signaling is required in β -catenin induced AML development. In patients with myelodysplastic syndrome or AML, 38.3% have increased β -catenin signaling and nuclear localization in osteoblasts. These patients also show a two-fold increase in NOTCH signaling in their hematopoietic cells compared to healthy controls. Mesenchymal stromal cells (MSCs) from AML patients have a higher level of Notch1 and jagged 1 expression compared to healthy controls. Pharmacological inhibitors of Notch significantly abrogate the survival effects of bonemarrow-derived stromal cells on leukemia cells from chemotherapy-induced apoptosis [16].

Activating mutations in *Ptpn11* gene (encodes protein tyrosine phosphatase SHP2) in the mouse bone marrow microenvironment hyperactivates cell proliferating pathways, including ERK, AKT, and NF- κ B in HSCs that drives myeloproliferative neoplasm (NPM) development. Interestingly, *Ptpn11* mutations in mesenchymal stem/progenitor cells and osteoprogenitors and not in differentiated osteoblasts, or endothelial cells induces the development of NPM. *Ptpn11* mutated mesenchymal stem/progenitor cells, or osteoprogenitors secrete an excessive amount of inflammatory CC chemokine CCL3 and matrix metalloproteinase inhibitor TIMP-1 that attracts monocytes in the area. Activated monocytes secrete proinflammatory cytokines, including interleukin-1 β , which hyperactivates HSCs residing in that area, resulting in the development of MPN [17]. Bone marrow MSCs secrete chemokine CXCL8 (also known as IL-8) that promotes AML cell proliferation and survival by activating the PI3/AKT survival

SUBJECT INDEX

A

- Acellular matrix 30
 Acetaldehyde-induced redistribution 70
 Actin 4, 5
 cytoskeleton elements 4
 polymerization 5
 Action 64, 143
 clinical antitumor 64
 controlled off-target 143
 Activated 35, 37, 90, 161
 C-kinase 37
 ERKs phosphorylate 35
 monocytes 161
 PI3K signaling pathway 90
 Activation 32, 34, 35, 37, 38, 40, 53, 54, 55, 57, 71, 90, 99, 100, 101, 102, 103, 104, 119, 137
 anomalous 119
 cofilin 71
 motif, tyrosine-based 137
 of CXCR4 by CXCL12 transduces 32
 of MAPK in pancreatic cancer 99
 Activity 4, 9, 10, 11, 14, 29, 33, 34, 35, 38, 60, 62, 64, 66, 68, 93, 106, 117, 118, 119, 122, 132, 135, 163, 166, 170, 174
 anticancer 106
 anti-inflammatory 122
 cytolytic 166
 decreasing enzyme 132
 demonstrated cytostatic 62
 enhanced EGFR receptor 66
 enzymatic 33
 lipase 135
 lipid phosphatase 68
 modulate Wnt pathway 9
 nuclear 118
 oncogenic 34, 53
 potentiated antitumor 62
 regulating NF- κ B 117
 regulatory cells 163
 restore tumor suppressor 93
 transcriptional 4, 38
 Acute myeloid leukemia microenvironment 165
 Adaptor proteins 35, 56, 137
 Agents 1, 8, 10, 14, 55, 60, 65, 71, 72, 85, 92, 105, 108, 121, 122
 block signaling pathways 55
 chemopreventive 10
 chemotherapeutic 14, 65
 therapeutic 1, 105
 Akt 108, 173
 suppress 173
 -mTOR signaling 108
 AML 159, 162, 165, 166, 168, 171
 cells overexpressing SET 171
 exosomes 165, 166, 168
 progression of 159, 171
 survival and proliferation 162
 xenografts 168
 AML cells 163, 164, 166, 168, 170, 171, 172, 173, 174
 mutant 173
 resistant 173
 Amphiregulin, low expression of 66
 Angiogenesis 30, 35, 55, 56, 57, 62, 87, 88, 90, 104, 105
 Antagonists 2, 31, 39, 120
 common CXCR4 31
 interleukin-1 receptor 120
 novel cyclic peptide 39
 Anti-EGFR 59, 60, 62, 65, 67, 72, agents 59, 72
 antibodies 62, 67
 mAbs 60, 72
 monoclonal antibodies 62, 65
 receptor therapy 59
 resistance pathway 72
 Apoptosis 53, 55, 57, 58, 69, 100, 101, 102, 103, 104, 106, 107, 108, 118, 132, 134, 161, 163, 168, 172
 angiogenesis apoptosis protein synthesis 55
 chemotherapy-induced 161, 163
 cytokine-induced 69
 drug-induced 163
 induced 58, 168

ATP-binding 131, 141
 domain 141
Auto-phagosomes-like compartments 137

B

Basal-like breast cancer 31, 37
 cells 31
B-cell 119, 139, 144
 illnesses 139
 lymphomas 119
 malignancies 144
BCR-dependent chemokines 142
Bone marrow 118, 140, 141, 160, 162, 165,
 167, 168, 169
 microenvironment (BMM) 118, 140, 141,
 160, 162, 165, 167
 multipotent 168
 stem cells 169
 stromal cells (BMSCs) 140, 141, 162, 168
 transplantation 160
Bone morphogenic protein (BMP) 2
Breast cancer 1, 3, 4, 5, 6, 7, 8, 10, 11, 13, 29,
 33, 36, 37, 38, 41
 metastatic 41
 stem cells 5, 10
Breast cancer cell 7, 12, 14, 35, 36
 lung carcinoma 12
 migration 35, 36
 motility 7
 sensitivity 14
Breast tumorigenesis 37
Bruton's tyrosine kinase (BTK) 120, 121, 131,
 132, 133, 134, 135, 136, 137, 139, 141,
 142, 144, 145
BTK 131, 133, 137, 138, 142, 143
 kinase inhibitor 143
 pathways 133
 signaling controls CLL cell movement 138
 signaling in hematological malignancies
 137
 signaling pathways 131, 133
 tyrosine phosphorylation 142
BTK inhibition 131, 132, 139, 140, 141, 145
 in hematological malignancies 131
BTK Inhibitors 131, 141, 143, 145
 small molecule 131
Burkitt's lymphoma 119

C

Cancer 5, 6, 8, 10, 38, 159
 signal transduction 159
 Stem Cells (CSCs) 5, 6, 8, 10, 38
Cancer cells 10, 11, 34, 37, 55, 58, 63, 65, 66,
 69, 102, 103, 104, 107, 108, 160, 164,
 165, 170
 growth of pancreatic 102, 104, 107
 human pancreatic 104
 invasive breast 37
 proliferation of pancreatic 102, 103, 104,
 108
 resistant 66
Cancer therapy 51, 65, 99
 pancreatic 99
Canonical 3, 100
 MAPK/ERK pathway 100
 Wnt signaling 3
 Wnt signaling pathway in breast cancer 3
Carcinogenesis 86, 114, 117, 118
Carcinoma-associated fibroblasts (CAFs) 30,
 38, 40
Carcinomas 56, 67
 gastric 56
Cell 34, 39, 133, 139, 140, 144, 145, 174
 division kinase (CDK) 34
 malignancies 133, 144, 145
 -matrix adhesions 39
 non-Hodgkin lymphoma 139, 140
 -penetrating small peptide 174
Cell lymphoma 12, 119, 134, 135, 145
 protein 135
Cerebrospinal fluid 165
Chemokine receptors 104, 135
 signaling 135
Chemokines 29, 30, 34, 100, 101, 136, 162
 oncogenic 34
Chemotherapy 8, 14, 35, 62, 65, 100, 160,
 163, 164, 165, 174
 irinotecan-based 62
 -resistant AML cells 164
Chimeric anti-TNF-antibody 120
Chronic lymphocytic lymphoma (CLL) 119,
 131, 137, 138, 139, 142, 144, 160
Chronic myelogenous leukemia (CML) 120,
 160, 162, 173
Cirrhosis 85
Colon cancer 10, 51, 62
 cells 10, 62

therapy 51
tissue 10
Colon carcinomas 56
Colorectal cancer 12, 51, 52, 59
metastatic 52, 59
Colorectal carcinoma 51
Competitive ATP inhibition 121
CREB binding protein (CBP) 3, 171
Cyclin-dependent kinase inhibitor 87
Cytokines 29, 30, 62, 66, 88, 99, 100, 101,
114, 116, 133, 162
chemotactic 29
inflammatory 66, 162
Cytoplasmic proteins harboring
phosphotyrosine-binding 53

D

Diarrhea 64
Dickkopf proteins 2
Diffuse large B-cell lymphoma (DLBCL) 119,
139, 140
Direct 58, 121
NF- κ B and nuclear activity inhibitors 121
visualization of endogenous expression of
EGFR 58
Disease 37, 38, 51, 52, 70, 71, 86, 92, 99, 106,
140, 162, 170
alcoholic liver 69
inflammatory bowel 52, 70
minimal residual 37, 38
osteolytic bone 140
prevalent human malignant 51
Disorders 69, 114, 132, 160
autoimmune 114
genetic 160
inflammatory 122
intestinal 69
myeloproliferative 160
DKK inhibitor delays AML progression 168
DNA 9, 87, 121, 159, 166, 167, 174
binding activity 121
damage signaling 9
hypermethylation 166
methylations 87
repair 174
Dose-limiting toxicity (DLT) 143
Downstream 57, 59, 100, 114, 142, 173
kinases 100
pathways 57, 59, 142, 173

target genes 114
Downstream signaling 53, 54, 62, 70
cascades 53, 54
molecule 70
pathways 62
Drug resistance 6, 34, 37, 39, 66, 159, 170
cytotoxic 170
Dysregulated Wnt signaling 6

E

EGFR 52, 59, 66, 67, 69, 71, 72, 90
degradation 58
-dependent mechanism 71
downstream cascade 71
inhibitors 59, 66, 67
overexpression of 52, 59, 90
pathway activation 66
phosphorylation of 66, 69
-targeted therapy 72
EGFR downstream 53, 54, 67
effectors 67
signaling 53, 54
signaling pathway 57
EGFR expression 51, 53, 58, 59, 70, 72
evaluating 59
increased 53
EGFR kinase 62, 65, 69
domains 62, 69
inhibitors 65
EGFR protein 59
expression 59
EGFR signaling 52, 53, 57, 58, 59, 62, 69, 70,
72
cascade 59
in macrophages acts 70
in myeloid cells 58, 69
Endogenous cell division kinase 34
Endothelial cells 29, 30, 140, 161, 164, 167
producing vascular 164
vascular 164
Endothelial progenitor cells (EPCs) 30, 38
Environment 103, 139, 167
pancreatic tumor 103
protective lymph nodes 139
Environmental toxins 29
Enzymatic complexes 103
Enzymes 12, 34, 39, 88, 103, 117, 122, 132,
135, 166
activation 135

cyclooxygenase 122
deubiquitinating 117
Epithelial-mesenchymal transition (EMT) 36
Erlotinib 55, 60, 61, 62, 64, 65, 68, 70
 and gefitinib 55, 60, 64
 combination of 64
 effect 64
ER-negative breast cancer 8
ER-positive breast cancer 8
Exosomes 37, 159, 164, 165, 166, 167, 168,
 172, 173, 174, 175
 cancer-derived 165
 levels of 165, 166
 secretion 167
Expression 6, 7, 36, 37, 40, 55, 56, 58, 68, 69,
 70, 93, 102, 104, 105, 118, 161, 166,
 168, 172
 c-Myc 172
 decreased 36, 70, 93, 105, 118, 168
 endogenous 58
 levels, decreased TGF β 166
 of ephrinA5 and EGFR expression 58

F

Factors 5, 7, 29, 32, 52, 59, 69, 88, 99, 100,
 101, 137, 139, 141, 160, 162
 angiogenic 88
 environmental 99, 101, 160
 extracellular 5
 infectious 29
 intracellular 5
 regulatory 2, 32, 137
 soluble 69
 tumor-related 59
 tumor-supporting 141
FAK-Src-paxillin signaling cascade modules
 32
Fc-receptor cross-linking, activating 137
Fibroblast(s) 30, 38, 58, 62, 87, 89, 160
 carcinoma-associated 30, 38
 growth factor (FGF) 58, 87, 89
 tumor-associated 62
Fibronectin 135, 142, 163
Focal adhesion kinase (FAK) 37
FOLFOX treatment therapy 64
Folinic acid 61, 63
Food and drug administration (FDA) 13, 65,
 120, 131, 141
Formation 3, 30, 117, 121, 140, 142

osteoblast bone 140
thrombus 142
Functions 20, 62, 120, 132, 166, 168, 169, 171
 cytolytic 166
 deregulate hematopoietic 168
 immune cell 166
 nervous system 132
 nuclear 120
 oncogenic 62
 proto-oncogene c-Myc 169
 stem cell 171
Fungi talaromyces 90
Furanosteroid metabolite 90
Fusion protein 172

G

Gene expression 57, 71, 100, 132, 140, 168
 cytokine 71
Genes 9, 11, 53, 54, 58, 86, 87, 115, 117, 119,
 161, 165, 166, 168
 breakpoint cluster region-Abelson leukemia
 166
 fluorescent reporter 58
 passenger cancer 86
 protein function 53, 54
 tumor susceptibility 165
Genome 5, 90
 amplification 5
 sequencing studies 90
Genomic alterations 86, 90
 somatic 86
Germline truncations 39
Glucocorticoids 120, 122
Glucose 34
 transporters 34
 uptake 34
Glycogen synthase kinase 3
G-proteins 30, 31, 35, 69, 93, 135
 coupled receptor (GPCR) 30, 69, 93
 heterotrimeric 31
 intracellular hetero-trimeric 135
 transmembrane 30
Groucho proteins 3
Growth 11, 56, 57, 93, 94, 101, 102, 103, 104,
 106, 107, 108, 162, 163, 165, 168
 reduced 168
Growth factor binding 2, 55
 protein 2

Growth factor(s) (GF) 30, 53, 54, 55, 56, 58, 63, 87, 88, 89, 91, 99, 100, 101, 105, 114, 116, 162, 163, 165, 166, 168
 connective tissue 57
 fibroblast 58, 87
 fibroblast-derived 87
 insulin 87
 signaling 87
 stimulation 88, 89
 transforming 54, 63, 166
 vascular endothelial 30, 87, 91, 105, 163, 168
 Guanine nucleotide-binding protein 135

H

Heat shock 165, 170
 factor 170
 proteins 165
 Hematopoietic 6, 160, 161, 164, 168, 173
 dysfunction 161
 stems cells (HSCs) 6, 160, 161, 164, 173
 Hepatitis B virus (HBV) 86
 Hodgkin's lymphoma (HL) 119
 Human umbilical vein endothelial cells (HUVECs) 168
 Hyaluronic acid 39
 Hydrolysis 67, 135

I

Immune 93, 140, 165, 166, 167, 172
 suppression 172
 system 93, 140, 165, 166, 167
 Immune responses 114, 132, 166, 165, 175
 adaptive 166
 Inflammatory 52, 70, 162
 bowel disease (IBD) 52, 70
 myelofibrosis 162
 Inhibition 6, 10, 34, 57, 68, 69, 70, 103, 104, 105, 106, 107, 117, 118, 122, 163, 170, 173
 angiogenesis 107
 of c-MYC 170
 of NF- κ B activation blocks MSCs 163
 ubiquitin-proteasome-induced 117
 Internal tandem duplication (ITD) 173
 Invasion 7, 33, 34, 35, 36, 37, 55, 56, 58, 100, 102, 103, 104, 117, 167

impaired 36
 leukemic 167
 tumor cell 7, 100, 117
 Irreversible BTK inhibitor 141, 142

K

Key 2, 36
 developmental pathway 2
 oncogenic proteins 36
 Kinase activities, intrinsic tyrosine 53, 54
 Kinases 3, 31, 33, 34, 35, 36, 88, 100, 101, 104, 142, 143, 170, 171
 phosphoinositide-dependent 88

L

Leukemia 12, 114, 119, 120, 131, 137, 160, 161, 162, 163, 164, 165, 167, 168, 169, 170, 171, 173, 174
 acute lymphoblastic 120, 160, 164, 170
 acute undifferentiated 174
 chemoresistance 163
 chronic lymphocytic 12, 131, 137, 160
 chronic myelogenous 120, 162
 chronic myeloid 160
 chronic myelomonocytic 160
 -derived exosomes 167, 169
 inhibitory factor (LIF) 163
 -initiating cell activity 164
 Leukemic cells, tumor microenvironment support 163
 Leukemic stem (LS) 162, 164
 cell functions 162
 Liver 69, 85, 86
 cancer 86
 cirrhosis 85, 86
 damage 69
 Low-grade dysplastic nodules (LGDNs) 86
 Luminal androgen receptor (LAR) 8, 9
 Lung metastasis 8, 36, 39
 inhibited 39
 Lymphocyte cytosolic protein 138
 Lymphoid enhancer-binding factor 3
 Lysophosphatidic acid 69

M

- Malignancies 6, 7, 99, 119, 122, 123, 132, 133, 145, 160, 165, 169
 hematologic 160
 human hematopoietic 169
 lymphoid 119
- Malignant monoclonal plasma cells 140
- Mammary adenocarcinoma 8
- Mantle cell lymphoma (MCL) 131, 139
- MAPK 58, 71, 99, 100, 101, 102
 -activated protein kinases 101
 activation 58, 99, 100, 101, 102
 pathway in pancreatic cancer progression 102
 protein phosphatases 101
 signaling cascade 71
 signaling inhibitors 108
- Markers 8, 51, 72, 102, 139, 165, 166, 173
- myeloid blast 166
- prognostic 102
- MCL-1 174
 protein expression 174
 therapy 174
- MCL cells in lymphoid tissues 139
- Mechanism 62, 65
 of blocking EGFR pathway by cetuximab 62
 of resistance to anti-EGFR therapy 65
- MEK 37, 71, 72, 106
 inhibitors 71, 72, 106
 inhibitors suppress growth 106
 pathway 37
- Melanoma cells 11
- Mesenchymal 8, 61, 161, 163
 stem-like (MSL) 8
 stem/progenitor cells 161
 mutated 161
 stromal cells (MSCs) 161, 163
- Metabolism 34, 57, 100
 cancer cell 34
- Metastasis 6, 8, 29, 30, 31, 34, 35, 37, 38, 39, 58, 85, 86, 102, 103, 104, 105
 antagonize tumor growth 29
 induced EGF-mediated 58
 reducing cancer 6
- Minimal residual disease (MRD) 37, 38
- Mitogen-activated protein kinase (MAPK) 31, 35, 39, 41, 72, 99, 100, 101, 102, 103, 104, 105, 106, 133, 135
- Mixed-lineage leukemia (MLL) 171
- MLL 171
 leukemia cells 171
 -transformed myeloid progenitors 171
- Modulated epigenetic regulation 7
- Morphogenesis, mammary gland 6
- Motif-containing GTPase-activating protein 33
- mRNA 34, 35, 59, 62, 165, 168
 expression 59
 helicase 35
 increased EGFR 62
- Mucin-type-O-linked glycosylation 69
- Multidrug resistance 6
- Multi-pass transmembrane protein 2
- Multi-tyrosine kinase inhibitor 92
- Mutations 1, 6, 51, 52, 119, 120, 139, 141
 genetic 52, 119, 120, 139, 141
 in EGFR family ligands 51
 in long-term stem cells 6
 in Wnt signaling 1
 loss-of-function 119
 recurring 139
 somatic 139
- Myelodysplasia 160, 161, 170
- Myelodysplastic syndrome 161, 163
- Myeloid-derived suppressor cells (MDSCs) 30, 172
- Myeloma 119, 131
 cells 119
 stem cells 131
- Myeloproliferative 161, 162
 neoplasia 162
 neoplasm 161
- Myosin light chain kinase (MLCK) 36

N

- Nausea 64
- Nemo-like kinase (NLK) 100
- Neoangiogenesis 38
- Neoplasms, lethal malignant 99
- Neurodegenerative disorders 12
- Neutrophils 30, 33, 36, 38, 70, 132, 160
 prometastatic 36
 tumor-associated 38
- NF- κ B inhibitors 120
- NK cell 166
 homeostatic cytokine 166
 suppression and immune invasion 166

- Non-canonical Wnt Pathways 4, 13
 - in breast cancer 4
- Non-Hodgkin lymphoma (NHL) 139
- Non-receptor tyrosine kinases 38
- Non-small cell lung cancer (NSCLC) 62, 64, 66
- Non-steroidal anti-inflammatory drugs (NSAIDs) 62, 120, 122
- Norepinephrine hormone 104
- Notch and bone morphogenic protein 2
- Nuclear 3, 116, 121
 - activity inhibitors 121
 - localisation signal 116
 - remodeling 3
- Nuclear factor 114, 170
 - kappa-light-chain-enhancer 114
 - of activated cells (NFATc) 170
- Nurse-like cells (NLCs) 138
- O**
- Oncogenesis 1, 14
- Oncogenic 36, 40, 68, 106
 - lesions 68
 - microRNA 106
 - mutations 40
 - transformation 36
- Oncogenic signaling 72, 159, 167, 174
 - pathways 159, 167, 174
- Osteoblasts 140, 161, 162, 164
 - murine 164
- Osteolytic lesions 119
- P**
- Paclitaxel efficacy in breast cancer 14
- PAF glycoproteins 101
- Pancreatic cancer 12, 14, 64, 99, 100, 102, 103, 104, 105, 106, 107, 108
 - adenocarcinomas 104
 - cell cycle progression 104
 - harbor mutations 102
 - malignancy 105, 108
 - malignant 103
 - metastatic 107
 - progression 102
 - tumorigenesis 104
- Pathways 3, 4, 34, 35, 40, 87, 88, 90, 93, 94, 99, 100, 117, 119, 123, 173
 - anabolic 35
 - dysregulated 40
- PCNA-associated factor (PAF) 103
- PCP 4, 5
 - and β -catenin-dependent Wnt signaling 5
 - pathway 4
- PDK1 34, 40
 - amplification 40
 - copy number 40
 - phosphorylates AKT 34
- Phagocytosis 137
- Phenotype 34, 162, 163, 166, 167
 - aggressive cancer 67
 - malignant 166
 - metastatic 34
 - senescence-associated secretory 162
- Phosphatase(s) 33, 37, 54, 57, 59, 66, 87, 132, 137, 140, 171
 - and tensin homolog protein 57
 - enzyme act 54
 - dual specificity protein 37
 - lipid 33
 - protein tyrosine 59
 - serinethreonine 171
- Phosphorylation 34, 35, 56, 57, 62, 88, 90, 92, 93, 116, 132, 134, 135, 139, 170, 171, 173
 - constitutive 139
 - destabilizes 170
 - histidine 92, 93
 - protein 132
- Platelet-derived growth factor (PDGF) 87
- Pleckstrin homology (PH) 33, 91, 133, 134, 136
- Post 6, 132
 - natal mammary fat pads 6
 - transcriptional modification 132
- Primary MCL cells 139
- Production 70, 103, 114, 137, 138
 - mucus 70
 - pro-inflammatory cytokine 137
- Progenitor cells 6, 30, 38, 86, 168
 - endothelial 30, 38
- Progesterone 8
- Prognosis 5, 7, 51, 100
 - worst 7
- Prognostic factor 169, 170, 172
 - important 169, 172
- Programmed cell death protein 35

- Progression 1, 9, 11, 53, 58, 60, 61, 63, 66, 67, 68, 88, 142
cancer cell 11
cell cycle 88
free-survival (PFS) 60, 61, 63, 66, 67, 68
inhibited colon cancer 58
neoplastic 53
oncogenic 1
primary leukemia 142
repressing cancer 9
- Progressive fibrosis 86
- Proliferation 7, 10, 67, 70
effects repressing breast cancer 7
epithelial 70
internalized complex suppressed 67
reducing colon cancer 10
- Promoter, downstream ARHGEF2 103
- Prompted lymphocytosis 139
- Proteases 162
- Proteasome 3, 4, 116, 118, 121
inhibitors 118, 121
- Proteins 2, 3, 5, 7, 8, 33, 35, 36, 38, 39, 55, 88, 89, 114, 115, 117, 132, 134, 135, 137, 165, 167, 171
anti-apoptotic 36, 134
histocompatibility 165
kinase C (PKC) 5, 55, 135
nucleocytoplasmic 114
phosphatase 3, 7, 171
-protein complexes 115
scaffold 33
stabilization 132
trans-membrane 132
synthesis 35
- Protein expression 53, 58, 59, 62
elevated EGFR 58
- Protein kinase 5, 31, 33, 39, 67, 99, 100, 107, 132, 135
activated mitogen-activated 99
mitogen-activated 31, 67, 100, 135
- Protein translation 36, 57
cap-dependent 36
- Protein-tyrosine kinase (PTK) 62, 131, 161
phosphatase receptor delta 62
phosphatase SHP2 161
- Proteolysis 37
- Putative oncogene zinc finger protein 103
- R**
- Radiation 52, 70, 114, 160
abdominal 52
mitigator, promising 70
- RAF 93, 101, 105
kinase inhibitory protein (RKIP) 101, 105
-MAPK pathways 93
-MEK-MAPK pathway 105
- Raf proteins 56, 67
- Rapamycin 33, 34, 91, 92, 57
mammalian target of 33, 57
- RAS 52, 55, 56, 57, 71, 63, 67, 68, 93, 99, 101, 103, 105, 136, 170
activated 105
gene 67
G-protein 101
mutation 63, 68, 71
-transformed pancreatic tumors 103
- Ras 34, 35, 36, 54, 56, 67, 93
-GTP 35, 56
homolog 34
/MAPK pathway 93
protein 54, 67
-Raf-ERK signaling cascade 56
- Reactive oxygen species (ROS) 103, 162, 166
- Receptor 52, 57, 59, 62, 65, 67, 88, 89, 91, 93, 101, 120
blockers and upstream signaling inhibitors 120
tyrosine kinase (RTKs) 52, 57, 59, 62, 65, 67, 88, 89, 91, 93, 101
- Regeneration 13, 70
tissue 13
- Regulated CREB-binding proteins 171
- Regulating 34, 57, 114
cell survival 114
EGFR signaling 57
glycolysis 34
- Regulator 4, 103, 116, 117, 167, 169, 171, 172
antiapoptotic 103
developmental 117
essential 167
important c-Myc 171
master transcriptional 169
- Regulators of Wnt signaling 5
- Represses transcription of Wnt-responsive genes 9
- Residues 36, 57, 101, 131, 134, 142, 170, 174
phosphor-tyrosine 57

phosphorylated 56
tyrosine 101
Resistance 51, 52, 58, 65, 66, 67, 68, 70, 71,
72, 100, 103, 105, 142, 159, 171, 173,
174
electrical 70
suppressing 58
therapy 159
Reverse-phase protein analysis 170
Rheumatoid arthritis 120
Rho 5, 36
-associated kinase 5
kinase 36
Ribosomal S6 protein 89

S

Secretion 37, 62, 71, 102, 137, 141
antibody 137
Serine 8, 11, 33, 35, 54, 67, 88, 142, 170, 174
dual specificity 35
kinase 33
mutation 142
/threonine kinase 8, 67, 88
SET 171, 174
oncoprotein 171
overexpression 171, 174
Signals 34, 102, 140, 162, 165, 170
immune-modulatory 162
mitogenic 170
pro-apoptotic 34
Signal transduction 86, 100, 102, 132
pathways 86
Single agent therapy 145
Solid tumors 12, 39, 40, 107, 117, 123, 171
advanced 107
Soluble Wnt agonists 13
Somatic hyper mutation (SHM) 138
Sonic hedgehog pathways 10
Sorafenib 71, 85, 92, 101, 107
treatment of 107
SOX transcription factors 9
Stem cell 1, 3, 38, 168
mesenchymal 38, 168
pluripotency 1
renewal 3
Stem-loop--structure (SLS) 36
Stress 29, 87, 101, 104, 114, 162
hormone norepinephrine 104
oxidative 29, 87, 101, 114, 162

response 101
Stromal cells 29, 30, 34, 37, 136, 162, 163,
168
multipotent 162
murine bone marrow 168
recipient bone marrow 168
Suppressor 166, 168
immune 166
Sustained activation of ERK pathway 37
Syndrome, hepatorenal 85

T

Target EGFR downstream signaling pathways
72
Tec protein tyrosine kinase 133
Tensin homolog protein 57
Therapeutic targets 2, 13, 70
effective 13
Therapies 13, 14, 41, 51, 60, 62, 65, 68, 99,
100, 106, 132, 138, 145, 159, 160, 164,
166
anti-cancer 132
long-awaited 145
pancreatic-cancer 106
Therapy resistance pathways 174
Threonine kinase protein 54
TLR and chemokine receptor signaling 135
TNF receptors 120
blockers 120
superfamily 120
Toll-like receptor (TLRs) 120, 132, 137
Toxicity 14, 29, 40, 64, 65, 106, 143, 144,
145, 174
dose-limiting 143
excess gastrointestinal 14
induced 174
minimal 29
perception 144
Toxin-mediated cellular injury 69
Trail blazing BTK inhibitor 131
Transcription factors, oncogenic 122
Transforming growth factor (TGF) 54, 63, 166
Translation 36, 38, 55, 88, 89
oncoprotein 36
Translational repressor protein 88
Triple-negative breast cancer (TNBC) 5, 6, 8,
9, 12, 13, 40
Tuberous sclerosis complex (TSC) 34, 87, 165
Tubulin polymerization 144

Tumor 7, 29, 30, 37, 38, 56, 58, 59, 86, 105, 162, 165, 169
aggressiveness 58
cell aggression 165
necrosis 29, 105, 162
progression 7, 29, 30, 37, 38, 56, 58, 59, 86, 169
relapse 38
repressor protein 105
Tumor cells 13, 30, 33, 36, 38, 104, 121, 162, 174
pancreatic 13, 104
primary 121
survival 33
Tumor development 59, 86, 138, 141
abolished 141
revoked 138
Tumor growth 7, 30, 39, 56, 57, 59, 67, 103, 104, 105, 106, 107, 120, 145, 162
factor 162
primary 39
reduced 67
regressed patient-derived human 106
support 30
sustainable 105
Tumorigenesis 7, 30, 31, 40, 57, 86, 104, 118, 120, 123
mammary gland 7
Tumor microenvironment 29, 30, 139, 142, 145, 159, 160, 162, 163, 165, 167, 172, 174
hematologic 159
immunosuppressive 29
modulate 162
Tumor suppressor 33, 34, 52, 54, 68, 70, 159, 166
genes 52, 54, 68, 70, 159, 166
proteins 33, 34
Tyrosine kinase 2, 35, 37, 38, 52, 53, 60, 62, 65, 92, 165, 168, 173
cytosolic 37
domain 60
inhibitors (TKIs) 60, 62, 65, 92, 173
intracellular 53
intracytoplasmic 52

U

Upregulation, transcriptional 34
Upstream 69, 93, 105, 108, 120

feedback inhibition 93
kinases 105, 108
blocking 120
Upstream receptor 35, 90
kinases 90
tyrosine kinase pathways 35
Upstream signaling 120
inhibitors 120
Ursolic acid 122

V

Vascular cell adhesion protein 163
Vascular endothelial growth factor (VEGF)
30, 55, 87, 88, 89, 91, 105, 117, 163, 167, 168
A (VEGFA) 87, 163
receptor (VEGFR) 89, 91, 168
VEGF in breast cancer cells 10

W

Waldenstrom macroglobulinemia (WM) 139, 142
Wnt 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 14
modulators 14
pathways 5, 7, 8, 9
proteins 2, 12, 13
regulators 5
secretion 2
target genes 3, 6, 10
Wnt signaling 1, 6, 7, 8, 10, 11, 14
cascade 1
in colon cancer tissue 10
of β -catenin 11
pathways 8, 11, 14
reduced 7
role of 6, 13

X

Xenograft model 67, 164
X-linked agammaglobulinemia (XLA) 132



Manoj K. Pandey

Manoj K. Pandey, Ph.D., is a faculty at Cooper Medical School of Rowan University (CMSRU), Camden, NJ, USA. Dr. Pandey earned his Ph.D. in Biochemistry from the Indian Institute of Toxicology Research (IITR) and Lucknow University, India. He accomplished his postdoctoral training at UT MD Anderson Cancer Center, Houston, TX. Dr. Pandey has authored more than 60 peer reviewed research articles, reviews, and book chapters in leading cancer biology and hematology oncology journals and served as Editor and Associate Editor of several journals. He is a member of the American Association of Cancer Research and American Society of Hematology.



Vijay P. Kale

Vijay P. Kale, B.V.Sc., M.V.Sc., Ph.D., DABT, ERT is a preclinical safety evaluation Scientist on anticancer drug development programs at Amgen Inc., California, USA. Dr. Kale has earned his Ph.D. from Penn State College of Medicine, Pennsylvania, USA. He has over 11 years of industrial experience in the drug discovery and development. Dr. Kale has authored several peer-reviewed research articles, abstracts at international scientific conferences, two book chapters, and delivered several oral presentations. He is a member of various scientific organizations such as AAAS, AACR, SOT, ACT, STP, STP-I and IAVP. He is certified as Diplomate of American Board of Toxicology (DABT) and is a European Registered Toxicologist (ERT).